Trials / Terminated
TerminatedNCT02856698
MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial)
Study Design and Rationale of "A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing MIdazolam Versus MOrphine in Acute Pulmonary Edema": MIMO Trial
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Alberto Dominguez-Rodriguez · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Acute pulmonary edema (APE) is a common condition in the emergency room, associated with considerable mortality. The use of intravenous morphine in the treatment of APE remains controversial and Benzodiazepines have been suggested as an alternative for morphine to relieving dyspnoea and anxiety in the patients with APE. The MIdazolan versus MOrphine in APE trial (MIMO) is a multicenter, prospective, open-label, randomized study designed to evaluate the efficacy and safety of morphine in patients with APE.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Midazolam | Dose use according to the product technical sheet |
| DRUG | Morphine | Dose use according to the product technical sheet |
Timeline
- Start date
- 2017-04-08
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
- First posted
- 2016-08-05
- Last updated
- 2022-06-09
- Results posted
- 2022-05-19
Locations
8 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT02856698. Inclusion in this directory is not an endorsement.